hotspot -WSS

hotspot

author：focus 2025-10-01 22:50:13 - browse：6735

The biotech company Acelyrin, which raised more than $500 million in an IPO this year, ran into its first major setback Monday as its investigational anti-inflammatory drug missed the primary goal in a pivotal clinical trial.

Acelyrin’s medicine, a subcutaneous treatment called izokibep, is meant to clear up lesions for patients with the common skin disease hidradenitis suppurativa, or HS, an inflammatory disorder that leads to abscesses and scars. But after 16 weeks of treatment, patients who received izokibep did not show significant improvements compared to those taking a placebo, failing the study’s primary endpoint.

Acelyrin’s share price fell more than 60% in after-hours trading Monday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Physician executives need more than on

hotspot

WSS

Achieving telehealth equity for people with hearing loss

Liquid biopsy for lung cancer is launched by Delfi

Achieving telehealth equity for people with hearing loss

Decentralized clinical trials need collaboration to achieve wider use

Bill would stop addiction treatment from triggering child abuse inquiry

Richard Slayman had a rejection episode of his pig kidney before leaving hospital

focus

hotspot

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

Some medical students still think black patients feel less pain

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

FDA authorizes Novavax’s updated Covid

After affirmative action ruling, medical educators look to 'holistic review'

Analysis of telehealth claims data suggest service duplication

DIEP, the 'gold standard' of breast reconstruction, is under threat

Bird flu makes raw milk dangerous to consume, mouse study finds

Activists slam private health insurers over coverage restrictions

Senate panel eyes new effort on drug shortages

focus

FDA panel signals lack of confidence in Amgen cancer drug data

Chan Zuckerberg Biohub Chicago to focus on inflammation

The world needs the new pandemic treaty

Sana to lay off nearly a third of staff, de

Bristol 'take

Bristol 'take

explore

hotspot

Wikipedia

knowledge